Skip to main content
Top
Published in: Diabetologia 1/2022

Open Access 01-01-2022 | Obesity | Article

Type 2 diabetes risks and determinants in second-generation migrants and mixed ethnicity people of South Asian and African Caribbean descent in the UK

Authors: Aliki-Eleni Farmaki, Victoria Garfield, Sophie V. Eastwood, Ruth E. Farmer, Rohini Mathur, Olga Giannakopoulou, Praveetha Patalay, Karoline Kuchenbaecker, Naveed Sattar, Alun Hughes, Krishnan Bhaskaran, Liam Smeeth, Nish Chaturvedi

Published in: Diabetologia | Issue 1/2022

Login to get access

Abstract

Aims/hypothesis

Excess risks of type 2 diabetes in UK South Asians (SA) and African Caribbeans (AC) compared with Europeans remain unexplained. We studied risks and determinants of type 2 diabetes in first- and second-generation (born in the UK) migrants, and in those of mixed ethnicity.

Methods

Data from the UK Biobank, a population-based cohort of ~500,000 participants aged 40–69 at recruitment, were used. Type 2 diabetes was assigned using self-report and HbA1c. Ethnicity was both self-reported and genetically assigned using admixture level scores. European, mixed European/South Asian (MixESA), mixed European/African Caribbean (MixEAC), SA and AC groups were analysed, matched for age and sex to enable comparison. In the frames of this cross-sectional study, we compared type 2 diabetes in second- vs first-generation migrants, and mixed ethnicity vs non-mixed groups. Risks and explanations were analysed using logistic regression and mediation analysis, respectively.

Results

Type 2 diabetes prevalence was markedly elevated in SA (599/3317 = 18%) and AC (534/4180 = 13%) compared with Europeans (140/3324 = 4%). Prevalence was lower in second- vs first-generation SA (124/1115 = 11% vs 155/1115 = 14%) and AC (163/2200 = 7% vs 227/2200 = 10%). Favourable adiposity (i.e. lower waist/hip ratio or BMI) contributed to lower risk in second-generation migrants. Type 2 diabetes in mixed populations (MixESA: 52/831 = 6%, MixEAC: 70/1045 = 7%) was lower than in comparator ethnic groups (SA: 18%, AC: 13%) and higher than in Europeans (4%). Greater socioeconomic deprivation accounted for 17% and 42% of the excess type 2 diabetes risk in MixESA and MixEAC compared with Europeans, respectively. Replacing self-reported with genetically assigned ethnicity corroborated the mixed ethnicity analysis.

Conclusions/interpretation

Type 2 diabetes risks in second-generation SA and AC migrants are a fifth lower than in first-generation migrants. Mixed ethnicity risks were markedly lower than SA and AC groups, though remaining higher than in Europeans. Distribution of environmental risk factors, largely obesity and socioeconomic status, appears to play a key role in accounting for ethnic differences in type 2 diabetes risk.

Graphical abstract

Appendix
Available only for authorised users
Literature
15.
go back to reference Grandinetti A, Kaholokula J, Theriault A, Mor J, Chang H, Waslien C (2007) Prevalence of diabetes and glucose intolerance in an ethnically diverse rural community of Hawaii. Ethn Dis 17(2):250–255PubMed Grandinetti A, Kaholokula J, Theriault A, Mor J, Chang H, Waslien C (2007) Prevalence of diabetes and glucose intolerance in an ethnically diverse rural community of Hawaii. Ethn Dis 17(2):250–255PubMed
20.
go back to reference Townsend P, Phillimore P, Beattie A (1988) Health and deprivation: inequality and the North. Croom Helm, Bristol Townsend P, Phillimore P, Beattie A (1988) Health and deprivation: inequality and the North. Croom Helm, Bristol
23.
go back to reference Everitt BS, Dunn G (2001) Confirmatory factor analysis and covariance structure models. In: Applied multivariate data analysis, 2nd edn. Wiley & Sons, Chichester, pp 291–307 Everitt BS, Dunn G (2001) Confirmatory factor analysis and covariance structure models. In: Applied multivariate data analysis, 2nd edn. Wiley & Sons, Chichester, pp 291–307
26.
go back to reference StataCorp (2017) Stata statistical software: release 15. StataCorp LLC, College Station, TX StataCorp (2017) Stata statistical software: release 15. StataCorp LLC, College Station, TX
27.
go back to reference Muthén LK, Muthén BO (1998–2017) Mplus user’s guide. Eighth Edition. Los Angeles, CA: Muthén & Muthén Muthén LK, Muthén BO (1998–2017) Mplus user’s guide. Eighth Edition. Los Angeles, CA: Muthén & Muthén
36.
go back to reference Ji Y, Yiorkas AM, Frau F et al (2019) Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes 68(1):207 LP – 219. https://doi.org/10.2337/db18-0708CrossRefPubMed Ji Y, Yiorkas AM, Frau F et al (2019) Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes 68(1):207 LP – 219. https://​doi.​org/​10.​2337/​db18-0708CrossRefPubMed
Metadata
Title
Type 2 diabetes risks and determinants in second-generation migrants and mixed ethnicity people of South Asian and African Caribbean descent in the UK
Authors
Aliki-Eleni Farmaki
Victoria Garfield
Sophie V. Eastwood
Ruth E. Farmer
Rohini Mathur
Olga Giannakopoulou
Praveetha Patalay
Karoline Kuchenbaecker
Naveed Sattar
Alun Hughes
Krishnan Bhaskaran
Liam Smeeth
Nish Chaturvedi
Publication date
01-01-2022
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2022
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-021-05580-7

Other articles of this Issue 1/2022

Diabetologia 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.